Supportive Cryotherapy: A Review from Head to Toe

Kunal C. Kadakia, MD, Shaina A. Rozell, MD, Anish A. Butala, BS, and Charles L. Loprinzi, MD
Division of Internal Medicine (K.C.K., S.A.R.), Mayo Clinic, Houston, Texas; Feinberg School of Medicine (A.A.B.), Northwestern University, Chicago, Illinois; and Division of Medical Oncology (C.I.L.), Mayo Clinic, Rochester, Minnesota, USA

Abstract

Context—Conventional chemotherapy leads to multiple adverse mucocutaneous complications including oral mucositis, alopecia, ocular toxicity, and onycholysis. Limited pharmacologic interventions are available for preventing these clinical problems.

Objectives—This study aimed to critically review the role of cryotherapy (regional hypothermia) for alleviating these adverse symptoms.

Methods—A narrative review was performed, with an emphasis on randomized controlled trials. A comprehensive search using PubMed, Ovid, Embase, and MEDLINE® was completed. References of all cited articles also were reviewed. Data from the review were comprised of articles published between 1970 to May 2013.

Results—Available evidence suggests that regional hypothermia decreases the burden of chemotherapy-related oral mucositis, alopecia, ocular toxicity, and onycholysis. The major limitations of studies include the absence of blinded control groups and variable clinical endpoints.

Conclusion—Regional hypothermia decreases the burden of these four chemotherapy-induced complications and is well tolerated. More research is needed to determine what subgroups of cancer patients are most likely to respond to different types of regional hypothermia, the ideal duration of cooling needed, and to further improve the ease of use of the cooling devices.

Keywords
Cryotherapy; regional hypothermia; mucositis; alopecia; onycholysis
**Introduction**

Conventional chemotherapy leads to adverse mucocutaneous complications such as oral mucositis, alopecia, onycholysis, and 5-fluorouracil (5FU)-related ocular toxicity. Despite extensive research, limited pharmacologic interventions are available for preventing these clinical problems. Cryotherapy utilizes the basic principle that cold-induced vasoconstriction can limit the local effects of certain cytotoxic therapies. This review critically appraises the role of cryotherapy in supportive oncology, focusing on the prevention of these four chemotherapy-induced complications.

**Oral Mucositis**

Oral mucositis (OM) causes oropharyngeal pain and can prevent adequate nutritional intake. Beyond causing significant pain and suffering,\(^1\) it is associated with increased hospitalizations, the need for total parenteral nutrition, and septicemia.\(^2,3\) As such, this complication leads to significant resource utilization and is a major economic burden.\(^4\)

**Pathogenesis of Oral Mucositis**

The pathogenesis of chemotherapy-induced mucositis is complex and yet to be fully understood. Although previously believed to be a nonspecific effect of chemotherapy on rapidly dividing cells of the mucosal tract, the pathobiology of mucositis has more recently been described as a sequence of five biological stages. These include initiation, upregulation and message generation (primary damage response), signaling and amplification, ulceration, and healing.\(^5\) Despite a better understanding of the pathogenesis of mucositis, multiple pharmacologic agents, posited to act at different stages of this sequence, have failed to show consistent benefits in randomized controlled trials (RCT).\(^6-9\) For example, glutamine, an amino acid necessary for cell mitosis, could theoretically decrease OM; however, its use has been poorly supported in adequately powered and well-designed RCTs.\(^10\) Other agents, such as palifermin, that interact at multiple stages in this sequence have proven to be beneficial in well-designed RCTs but are only a U.S. Food and Drug Administration-approved preventative agent in certain patients undergoing autologous hematopoietic stem cell transplantation (HSCT).\(^11\)

**Cryotherapy and Oral Mucositis**

The mechanism of oral cryotherapy, placing ice chips in the mouth during chemotherapy infusion for the prevention of OM is, at least hypothetically, understood. When developed, it was assumed that such a maneuver would decrease the temperature of the oral cavity. A recent study of 12 healthy patients confirmed that crushed ice in the oral cavity leads to a mean difference of \(\approx 13^\circ\) C in the oral cavity tissues.\(^12\) Hypothermia leads to vasoconstriction and the resultant reduction in blood flow is posited to decrease the local effects of concentrated levels of cytotoxic drugs in the cooled area.

Since 1991, over 20 controlled and uncontrolled trials have assessed the efficacy of oral cryotherapy for the prevention of OM (Tables 1 and 2). Almost all trials studied its effectiveness in patients receiving chemotherapeutics with a short serum half-life, such as bolus 5FU and high-dose melphalan. Mahood et al. were the first to observe that...
cryotherapy reduced 5FU-induced OM, by ~50%. In a confirmatory analysis, 84 patients were randomized to either oral cryotherapy or control and a similar reduction in the mean OM toxicity score was observed. Following the results of these pivotal trials, French and Italian researchers found cryotherapy effective in reducing OM in patients undergoing conditioning regimens containing high-dose melphalan. However, one of the limitations of these early trials was that they did not assess for pre-treatment oral health. Although the optimal regimen of oral care remains to be determined, maintaining adequate oral hygiene prior to and following chemotherapy and radiation appears to reduce the incidence and severity of OM.

Beyond reducing the incidence of OM in patients receiving such chemotherapy, further trials have demonstrated the effectiveness of cryotherapy in reducing the duration of OM, its effect with different chemotherapeutic regimens, utility with other prophylactic agents, and the optimal duration of cryotherapy itself.

In 2005, 60 patients with solid tumors receiving varying combinations of etoposide, cisplatin, vinblastine, and mitomycin were randomized to cryotherapy or standard treatment. The patients allocated to cryotherapy had less mucositis as well as a shorter mean duration of OM (7 vs. 12 days). The shortened course of OM also was observed in other trials, most averaging a reduction of approximately four days.

Edatrexate, an analogue of methotrexate with a short serum half-life, has been used with marginal success in regimens for both solid and liquid tumors, with the major dose-limiting side effects being OM and myelosuppression. In a phase I trial of 46 patients receiving edatrexate plus carboplatin in advanced solid tumors, only 15% had Grade 3/4 OM with the use of cryotherapy, less OM than was seen in trials not using cryotherapy. Two other trials found mixed results with cryotherapy in patients receiving edatrexate.

Although allopurinol mouthwashes alone do not consistently appear to prevent OM, its role combined with cryotherapy (i.e., allopurinol ice balls) was shown to be promising in a Japanese trial. In contrast to all previous trials, the patients were administered allopurinol ice balls during the infusion as well as at two, four, and six hours post-infusion. To address whether a longer duration of cryotherapy in patients receiving 5FU is needed, 178 patients were randomized to either 30 or 60 minutes of cooling and no difference was observed between groups, supporting that 30 minutes was adequate.

Five more recent trials also have reported a clear benefit of oral cryotherapy over standard care alone in patients receiving 5FU. The earliest of these found a clear benefit of either oral cryotherapy regimen over control; however, no patient preference of flavored vs. plain ice cryotherapy was observed. Patients receiving flavored ice were more likely to complain of nausea, oral sensitivity, and headaches. Papadeas et al. confirmed the persistent benefit of oral cryotherapy over three cycles of chemotherapy. In the largest RCT to date, oral cryotherapy and chlorhexidine significantly decreased the incidence of Grade 3 OM over normal saline. Compliance rates were the highest for the cryotherapy arm; however, this arm was associated with significantly more headaches.
In patients undergoing melphalan-containing conditioning regimens, initial reports suggested the benefit of oral cryotherapy in nonrandomized studies as described above.\textsuperscript{15, 16} Since then, three nonrandomized and three randomized studies have shown significant benefit for OM with the use of oral cryotherapy in this patient population (Table 2).\textsuperscript{15, 16, 33-38} To address the optimal duration of cryotherapy in patients receiving melphalan, a study found that a total duration of cryotherapy for 60 minutes compared with 120 minutes improved tolerability without decreasing efficacy.\textsuperscript{36} Other studies in patients undergoing HSCT have shown that oral cryotherapy also reduces opioid use\textsuperscript{37} and decreases the need for parenteral nutrition.\textsuperscript{38}

Despite the above positive data, a large randomized multicenter study found no significant difference between cryotherapy compared with standard therapy in patients receiving low-dose methotrexate following allogeneic HSCT (47% vs. 53%).\textsuperscript{39} Although the researchers found that peak methotrexate plasma levels occur within 30 minutes of infusion, the elimination half-life and methotrexate by-products likely decreased the efficacy compared with studies involving melphalan and 5FU. Given the large number of positive studies and virtual lack of negative studies (except for the study noted above), it is reasonable to consider a potential publication bias. However, it is unlikely that there is more of a publication bias in this setting versus other settings with multiple positive studies.

**Adverse Effects of Cryotherapy for Oral Mucositis**

Most patients tolerate oral cryotherapy without serious issues. The most common adverse effects reported include headaches, nausea, and chills. Some patients note a subsequent aversion to ice, as it can bring back memories of other chemotherapy-induced toxicities such as dysgeusia. A recent report found no serious adverse effects such as an increased relapse rate in hematological cancers over a five-year period.\textsuperscript{40}

**Chemotherapy-Induced Alopecia**

Chemotherapy-induced alopecia (CIA) is a common and distressing adverse effect of cancer treatment that can negatively impact quality of life.\textsuperscript{41-43} The incidence and severity of alopecia is dependent on the route, dose, and schedule of the cytotoxic drugs utilized.\textsuperscript{44} Hair loss generally occurs two to four weeks after the initiation of chemotherapy and regrowth occurs three to six months following cessation of therapy, although irreversible hair loss does rarely occur.\textsuperscript{45, 46} Therapy to prevent the occurrence of alopecia is desired as it is a feared complication of cancer treatment, and nearly 10\% of women would consider refusing chemotherapy because of it.\textsuperscript{47-50}

**Pathogenesis of Chemotherapy-Induced Alopecia**

The pathophysiology of CIA is complex and not fully understood. Much of the understanding has been gleaned from studies involving newborn rats, the C57BL/6 mouse model, and more recently an adult rat model.\textsuperscript{51-53} Two broad mechanisms are felt to be responsible for hair loss: thinning of the hair shaft leading to breakage and inhibition of dividing hair matrix cells resulting in hair separation from the bulb (anagen effluvium). Both processes are related, in part, to the capacity of cytotoxic therapy to impair mitotic activity.
and induce apoptosis. The molecular mechanisms of chemotherapy-induced apoptosis continue to be elucidated and activation of p53 plays a critical role in the devolvement of CIA.\textsuperscript{54}

Delivery of scalp hypothermia (i.e., cryotherapy) can occur in the form of an ice turban, gel cap, cool cap, or a thermocirculator. It involves physically decreasing the amount of cytotoxic drug that is delivered to the scalp. It is theorizd that scalp hypothermia triggers vasoconstriction of local blood vessels, thereby limiting temperature dependent absorption of cytotoxic therapy and reducing local tissue metabolism by the hair follicle.\textsuperscript{55, 56}

**Cryotherapy and Chemotherapy-Induced Alopecia**

In the 1970s, scalp hypothermia was initially reported to improve alopecia in patients receiving doxorubicin.\textsuperscript{57-59} Since then, there have been more than 50 nonrandomized and seven randomized studies evaluating its efficacy in diverse patient populations; patients with breast cancer remain the most studied group. A comprehensive review, published in 2005, concluded that the majority of findings were positive, with an average success rate prior to and after 1995 of 56\% and 73\%, respectively (most often based on the World Health Organization [WHO] alopecia grading criteria and less frequently on the need for a wig or a head cover).\textsuperscript{60} Six of the seven randomized trials (N=233) published to date were positive and, of these, five occurred in the 1970s and 1980s,\textsuperscript{58, 61-64} whereas only two were more recent.\textsuperscript{65, 66} Although the chemotherapy regimens used in these earlier studies differed from more recent studies, other methodological variables including scalp-cooling technique, post-infusion cooling times, duration of chemotherapy infusion, and eligibility criteria make comparisons between studies difficult.

Since the review published in 2005,\textsuperscript{60} there have been nine studies evaluating the efficacy of scalp hypothermia (one systematic review and eight nonrandomized studies) (Table 3). The systematic review only included three of the older randomized controlled studies because of methodological issues and tentatively recommended the use of scalp hypothermia.\textsuperscript{67} In 2009, a study involving breast cancer patients found that scalp hypothermia significantly reduced the need for a wig or a head cover compared with control.\textsuperscript{68} Scalp hypothermia was felt to be burdensome in a minority of the group (33\%), with a common concern being that scalp cooling will fail to prevent hair loss. In a separate analysis by the authors, successfully cooled patients had an improved feeling of well-being; however, patients who were unsuccessfully cooled reported the highest degree of distress.\textsuperscript{43}

In another study of 64 patients, primarily with breast cancer, 83\% of patients using a scalp-cooling gel-cap reported Grade 0/1 alopecia and only 17\% had Grade 3 alopecia.\textsuperscript{69} The majority of patients did not report any side effects (57\%), and tolerable side effects were reported by 30\%. Only four patients discontinued the use of the scalp-cooling gel-cap because the process was too unpleasant or cold.

In 2011, Karger et al. completed a study of 63 patients with various cancers and compared the scalp-cooling group with a control group; they found greater benefit earlier in the course of therapy, suggesting a component of cumulative toxicity from chemotherapy leading to
less benefit from scalp cooling during subsequent cycles. The authors did not mention any significant adverse effects of therapy.

The largest cohort ever studied, comprising 1411 patients from the Dutch Scalp Cooling Registry, found that the overall use of head covering (wig or other) was 50% within the entire cohort but varied from 5-10% with low-dose docetaxel or paclitaxel to more than 90% of patients receiving combination regimens. Higher chemotherapy doses, shorter infusion times, non-Western European hair, female gender, and older age were associated with a higher use of head covers. Median pre- and post-infusion cooling times were significantly longer than the reported pre- and post-infusion times in the more recent studies. A subsequent study by the same authors found that a shorter post-infusion cooling time was as effective as a longer post-infusion cooling time (45 vs. 90 minutes).

A recent prospective cohort study, available only in abstract form, found that scalp hypothermia significantly reduced alopecia compared with a control group. Compared with hairstylist assessments, patient-reported assessments suggested a greater degree of benefit, highlighting the significance of patient expectations in this study. Adverse effects and quality-of-life measurements are yet to be published.

The most recent study comparing the Paxman cooling system with another cold cap (manufacturer not specified) found a significant decrease in alopecia in patients receiving either form of scalp hypothermia. Importantly, a shorter post-infusion cooling time (45 vs. 90 minutes) was again found to be effective.

**Adverse Effects of Scalp Hypothermia**

Most patients tolerate scalp hypothermia well; however, a few may find it too cumbersome, lengthy, or intolerable. Although uncommon, adverse effects include headaches, extreme coldness, or a heavy sensation. Rare side effects include nausea, dizziness, or anxiety.

**Risk of Scalp Metastases and Influence of Drug Metabolism**

Two case reports of scalp metastases associated with scalp hypothermia in patients with hematological malignancies have been reported. Although similar concerns have been raised in patients with solid tumors, more recent evidence suggests that this risk is minimal. The incidence of scalp metastases was 0.45% in one large retrospective study (two of 442 patients). The incidence of scalp metastases in another retrospective cohort was similar in patients undergoing scalp hypothermia or not (1.1% vs. 1.2%). The large Dutch registry of 1411 patients has yet to observe a scalp metastasis within its entire cohort. Given the lack of supporting data to suggest safety in patients with hematological malignancies and the aforementioned case reports, scalp hypothermia is not recommended for this population.

Initial reports of severe alopecia in patients with liver insufficiency treated with doxorubicin despite scalp hypothermia suggest the influence of drug metabolism as a predictor of scalp hypothermia failure. More recent studies also suggest that liver insufficiency could lead to higher rates of alopecia despite scalp hypothermia.
Chemotherapy-Induced Onycholysis

A variety of changes to the nail can occur because of chemotherapy including onycholysis (detachment or loosening of the nail from the nail bed). Beyond aesthetic disfigurement, onycholysis can be painful, can increase the chance of superimposed infection and can delay chemotherapy administration. It is most commonly associated with taxanes including docetaxel and paclitaxel but its occurrence because of other chemotherapeutic agents can occur. The incidence of taxane-induced onycholysis is variable (5-30%) depending on the specific taxane used (the risk with docetaxel is greater than that with paclitaxel) and the dosing schedule.

Pathogenesis of Chemotherapy-Induced Onycholysis

Although the etiology of chemotherapy-induced onycholysis remains to be elucidated, direct cytotoxic, vascular, and neurogenic mechanisms have been postulated. A thin nail bed epithelium is responsible for supporting the adhesion of the nail plate to the nail bed. Chemotherapy-related cytotoxic injury to this epithelium could contribute to the development of onycholysis. A neurogenic mechanism was first proposed based on the sparing of toxicity in the paretic hand of a patient who had docetaxel-induced onycholysis in the other three extremities. The authors hypothesized two particular neurogenic mechanisms: the first is related to persistent neurogenic inflammation from taxane-induced stimulation of cutaneous nociceptive C-fibers and the second is related to taxane-induced release of pro-inflammatory mediators that promote maintenance of nociceptive primary afferent stimulus (peripheral sensitization).

Cryotherapy and Chemotherapy-Induced Onycholysis

Similar to scalp hypothermia and oral cryotherapy, the suspected mechanism of regional hypothermia in the prevention of onycholysis is likely related to local vasoconstriction leading to reduced levels of cytotoxic drug to the nail bed and matrix. Based on the efficacy of cryotherapy for alopecia and mucositis, multiple studies evaluating regional hypothermia for prevention of nail toxicity have been completed (Table 4). Scotté et al. reported a case-control trial of 45 patients, using an Elasto-Gel frozen glove with the patient’s left hand used as a control, for the prevention of docetaxel-induced onycholysis and skin toxicity. Nail toxicity was significantly less in the frozen glove protected hand. Most patients were satisfied with treatment. However, 11% withdrew because of cold intolerance. The same authors conducted a similarly designed matched case-control trial using a frozen sock and found significantly less docetaxel-induced onycholysis and skin toxicity in the protected foot. Only one patient was dissatisfied with the treatment because of cold intolerance. Two further studies, each reported in abstract form, found similar benefits with frozen glove therapy with no serious adverse effects reported except discomfort.

To evaluate the ideal duration and degree of cooling necessary to prevent nail toxicity and maintain comfort, Ishiguro et al. compared a standard frozen glove worn for 90 minutes to a glove worn for 60 minutes. At five months, patients in the 60-minute group had a similar degree of nail toxicity with less discomfort, suggesting that the shorter duration intervention
worked as well as the more intense treatment. Docetaxel exposure over the study period did not correlate with nail toxicity.

Despite the aforementioned positive studies, a recent study of 55 patients receiving either taxane were treated with frozen gloves and socks on all extremities and were compared with a similar cohort; no statistical difference was observed in nail toxicity between groups. Possible explanations for the lack of effect observed include the variety of chemotherapy regimens used in both groups and, more importantly, the differences among individuals, as opposed to each individual being their own control (i.e., using one side to compare to the other).

**Adverse Effects of Extremity Hypothermia**

The major adverse effect observed in clinical studies includes discomfort related to the degree of cooling and the duration of use. A minority of studied patients (≈2-10%) stopped the intervention because of discomfort. One case report described frostbite occurring in the fingers of a man who used frozen gloves (cooled to −25 to −30°C and worn for 90 minutes) during one cycle of docetaxel therapy, which improved with supportive care and subsequent avoidance of frozen gloves.

**5FU-Related Ocular Toxicity**

Many types of ocular toxicity related to anticancer treatments have been described in patients receiving cytotoxic as well as targeted therapy. Ocular toxicities related to 5FU can be divided into complications of the ocular surface, ocular adnexa, or the lacrimal system. Based on 210 patients, receiving a variety of chemotherapy agents, unpleasant ocular symptoms were reported by ≈40% of patients receiving 5FU-containing regimens compared with ≈20% of patients receiving non-5FU-containing regimens, suggesting a strong association of 5FU exposure with ocular toxicity. The most frequent adverse symptoms included tearing (27%), blurred vision (11%), ocular irritation with pain (6%), and eyelid dermatitis (6%). 5-FU-related ocular symptoms generally occur within 11 to 17 days of the infusion and resolve after 10-15 days. Although not life-threatening, these adverse symptoms can cause suffering and delay chemotherapy administration.

**Pathogenesis of 5FU-Related Ocular Toxicity**

Damage of the conjunctiva, cornea and the eyelid margin within days to weeks of 5FU administration is likely related to the cytotoxic effect on the rapidly proliferating cellular elements of these ocular surfaces. Two proposed mechanisms for the etiology of tearing, the most common adverse effect, have been suggested. One theory postulates a reflex phenomenon as a result of direct cytotoxic irritation of the ocular surface. As drug levels are detectable in tears of patients receiving 5FU, the second theory proposes irritation of the lacrimal gland leading to hypersecretion. Concentrations of 5FU in tears, in a small series of 12 patients, were not found to be associated with adverse symptoms, but were associated with symptoms in another series of 13 patients. More prolonged administration of 5FU (more than three months) can lead to chronic inflammation of the lacrimal system.
and has been associated with punctal-canalicular stenosis that can rarely result in permanent excessive lacrimation requiring surgical correction.\textsuperscript{103}

**Cryotherapy and 5FU-Related Ocular Toxicity**

In 1990, an initial report of eight patients receiving cyclophosphamide, methotrexate, and 5FU (CMF), who had ocular toxicity on a previous cycle of CMF, were treated with ice packs over their eyes for a total of 30 minutes prior to and during the 5FU infusion. The majority had a decrease in adverse ocular symptoms during the next month.\textsuperscript{98} The postulated mechanism is likely similar to that of cryotherapy for other indications, in that regional hypothermia induces constriction of the blood vessels around the eye resulting in reduced cytotoxic effect during peak 5FU serum concentration. Based on these pilot data, a randomized crossover trial was conducted in 62 patients who had previously complained of ocular toxicity and were undergoing additional 5FU therapy.\textsuperscript{104} Ice packs were provided five minutes prior to bolus 5FU infusion and continued for a total of 30 minutes. Mean total ocular toxicity was reduced in patients receiving ocular ice therapy (20 vs. 29 units, $P=0.056$). Although generally well tolerated, unpleasant side effects, such as “feeling cold,” “sore sinuses,” and headaches occurred in 22\% of patients.

**Conclusions for Supportive Cryotherapy**

The majority of studies addressing the use of supportive cryotherapy have shown benefit in preventing oral mucositis, alopecia, onycholysis, and 5FU-related ocular toxicity. The major limitations of these studies are the variability of study design and the lack of blinding. The latter issue is not technically feasible given the nature of the intervention. Although the ideal technique for providing supportive cryotherapy for each of these issues remains to be elucidated, a few conclusions can be made.

Oral cryotherapy has demonstrated a reduction in incidence, severity, and duration of OM (by approximately 50\% compared with standard care) in multiple controlled studies involving patients with a variety of cancers receiving bolus 5FU and conditioning regimens containing melphalan. Its role with other cytotoxic regimens such as edatrexate is promising. However, it would not be expected to be effective with chemotherapeutics with longer half-lives. In patients receiving bolus 5FU, crushed ice should be given five minutes prior to infusion and be continued for at least 30 minutes. Based on available evidence, the duration of cryotherapy in patients receiving melphalan-containing conditioning regimens can be increased to 60 minutes, if tolerated. A recent systematic review\textsuperscript{105} and the most recent Multinational Association of Supportive Care in Cancer oral mucositis guidelines\textsuperscript{106} support these recommendations. Areas of potential further research include the role of oral cryotherapy with other chemotherapy regimens, its efficacy in pediatric populations, and comparisons with promising pharmacological interventions used for OM.

Scalp hypothermia reduces the burden of chemotherapy-induced alopecia. Its role has largely been studied in patients with breast cancer; however, significant distress related to alopecia in male cancer patients warrants further investigation in this population.\textsuperscript{107, 108} Although the ideal technique for cooling has yet to be elucidated, recent reports have yielded promising data regarding the optimal degree of cooling necessary\textsuperscript{55} and the duration of post-
infusion cooling. Further studies comparing different cooling techniques are needed. Finding more user-friendly means of providing effective scalp hypothermia would be helpful. As research progresses, formal guidelines regarding the role of cryotherapy for alopecia will be warranted.

Although nail toxicity is not life threatening, onycholysis can be disfiguring, painful, and delay chemotherapy administration. The majority of clinical data supports that regional hypothermia of the hands and feet decreases the incidence of onycholysis, with minimal discomfort. It appears to be most consistently effective in patients receiving one-hour infusions of docetaxel. A single trial reported similar benefit with a more tolerable regimen (glove cooled to −10 to −20°C and worn for 60 minutes compared with −25 to −30°C for 90 minutes).93

Cryotherapy also appears to be an effective and tolerable intervention for short-term ocular toxicity related to bolus 5FU infusions. Many current chemotherapy regimens, however, utilize continuous infusions of 5FU, and cryotherapy would likely not provide benefit for these patients. Although largely of historical significance, ocular ice therapy further supports the role of regional hypothermia for certain chemotherapy-induced complications.

Acknowledgments

This work was supported by National Institutes of Health Grant CA 124477 (Principal Investigator: Charles Loprinzi, MD).

References


92. Sakurai M, Todaka K, Takada N, et al. Multicenter phase II study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity for the breast cancer patients (Kinki


J Pain Symptom Manage. Author manuscript; available in PMC 2015 June 01.
# Table 1

## Studies of Oral Cryotherapy in Solid Malignancies

<table>
<thead>
<tr>
<th>Reference</th>
<th>Year</th>
<th>Randomized</th>
<th>No. in Intervention/Control Group</th>
<th>Type of Cryotherapy</th>
<th>Duration of Cryotherapy</th>
<th>Chemo Regimen</th>
<th>Mucositis Staging</th>
<th>Intervention Group</th>
<th>Control Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mahood(^{13})</td>
<td>1991</td>
<td>Yes</td>
<td>50/45</td>
<td>Ice chips</td>
<td>5 min pre-5FU and then for 30 min</td>
<td>5FU/LV</td>
<td>Mean patient and physician judged mucositis grading (0-4), mean score</td>
<td>Patient: 1.1</td>
<td>Physician: 0.9</td>
</tr>
<tr>
<td>Rocke(^{30})</td>
<td>1993</td>
<td>Yes</td>
<td>89/89(^{a})</td>
<td>Ice chips</td>
<td>5 min pre-5FU and then for 30 or 60 min</td>
<td>5FU/LV</td>
<td>Mean patient and physician judged mucositis grading (0-4), mean score</td>
<td>Patient: 30 min: 0.73</td>
<td>60 min: 1</td>
</tr>
<tr>
<td>Cascinu(^{14})</td>
<td>1994</td>
<td>Yes</td>
<td>44/40</td>
<td>Ice chips</td>
<td>5 min pre-5FU and then for 30 min</td>
<td>5FU/LV +/- etoposide or interferon</td>
<td>Combined patient and physician judged mucositis grading (0-4), mean score</td>
<td>0.59</td>
<td></td>
</tr>
<tr>
<td>Dreicer(^{25})</td>
<td>1997</td>
<td>No</td>
<td>37(-)</td>
<td>Ice chips</td>
<td>30 min prior to edetrexate infusion</td>
<td>Edatrexate</td>
<td>ECOG grade, Grade 3-4</td>
<td>38%</td>
<td></td>
</tr>
<tr>
<td>Gandara(^{26})</td>
<td>1997</td>
<td>No</td>
<td>23(-)</td>
<td>Ice chips</td>
<td>5 min pre, during, and 15 min after edetrexate infusion</td>
<td>Edatrexate + carboplatin</td>
<td>Not specified, Grade 3</td>
<td>13%</td>
<td></td>
</tr>
<tr>
<td>Edelman(^{22})</td>
<td>1998</td>
<td>No</td>
<td>46(-)</td>
<td>Ice chips</td>
<td>5 min pre, during, and 15 min after edetrexate infusion</td>
<td>Edatrexate + carboplatin</td>
<td>CTC, Grade 1-4</td>
<td>Grade 1-2: 59%</td>
<td>Grade 3-4: 15%</td>
</tr>
<tr>
<td>Hades(^{19})</td>
<td>1999</td>
<td>No</td>
<td>27(-)</td>
<td>Ice chips</td>
<td>5 min pre-5FU and then for 30 min</td>
<td>5FU/LV + interferon</td>
<td>CTC, Grade 3-4</td>
<td>36%</td>
<td></td>
</tr>
<tr>
<td>Yokomizo(^{29})</td>
<td>2004</td>
<td>No</td>
<td>20/32</td>
<td>Allopurinol ice balls</td>
<td>Prior to 5FU infusion and at 2, 4, and 6 hours until melted</td>
<td>5FU/LV</td>
<td>CTC, Grade 1-4</td>
<td>Grade 1-2: 15%</td>
<td>Grade 3-4: 0%</td>
</tr>
<tr>
<td>Karagozoglou(^{20})</td>
<td>2005</td>
<td>Yes</td>
<td>30/30</td>
<td>Smooth ice cubes</td>
<td>5 min pre-chemo until all infusions complete</td>
<td>Etoposide, cisplatin, mitomycin, vinblastine</td>
<td>Patient and physician judged mucositis grading (0-4), Grade 1-4</td>
<td>Patient: 37%</td>
<td>Physician: 10%</td>
</tr>
<tr>
<td>Nikoletti(^{31})</td>
<td>2005</td>
<td>Yes</td>
<td>67/67/67(^{a})</td>
<td>Plain ice or flavored ice</td>
<td>5 min pre and during, until 20 min after 5FU</td>
<td>5FU +/- LV</td>
<td>Oral Assessment Guide, OR(^{c})</td>
<td>None vs. Plain: 3.26</td>
<td>None vs. flavored: 3.5</td>
</tr>
<tr>
<td>Reference</td>
<td>Year</td>
<td>Randomized</td>
<td>No. in Intervention/Control Group</td>
<td>Type of Cryotherapy</td>
<td>Duration of Cryotherapy</td>
<td>Chemo Regimen</td>
<td>Mucositis Staging</td>
<td>Intervention Group</td>
<td>Control Group</td>
</tr>
<tr>
<td>-----------</td>
<td>------</td>
<td>------------</td>
<td>----------------------------------</td>
<td>---------------------</td>
<td>-------------------------</td>
<td>---------------</td>
<td>------------------</td>
<td>-------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Baydar(^{10})</td>
<td>2005</td>
<td>Yes</td>
<td>45/54(^{d})</td>
<td>Ice chips</td>
<td>Start of infusion until 10 min after 5FU</td>
<td>5FU/LV</td>
<td>WHO, Grade 1-3</td>
<td>7% (only Grade 1)</td>
<td>39% (Grade 1-3)</td>
</tr>
<tr>
<td>Papadeas(^{12})</td>
<td>2007</td>
<td>Yes</td>
<td>36/40</td>
<td>Crushed ice</td>
<td>5 min pre and during, until 30 min after 5FU</td>
<td>5FU/LV</td>
<td>Patient and physician judged mucositis grading (0-4); Grade 3</td>
<td>Patient: 17%</td>
<td>Physician: 11%</td>
</tr>
<tr>
<td>Sorensen(^{11})</td>
<td>2008</td>
<td>Yes</td>
<td>70/64/63(^{e})</td>
<td>Crushed ice</td>
<td>10 min pre-5FU and then for 35 min</td>
<td>5FU/LV</td>
<td>CTC, Grade 3</td>
<td>Cryotherapy: 10%</td>
<td>Chlorhexidine: 11%</td>
</tr>
<tr>
<td>Katrancı(^{11})</td>
<td>2011</td>
<td>Yes</td>
<td>30/30</td>
<td>Crushed ice</td>
<td>5 min pre, during, and up to 15 min after 5FU</td>
<td>5FU/LV</td>
<td>WHO, Grade 3</td>
<td>3%</td>
<td>20%</td>
</tr>
</tbody>
</table>

5FU = 5-fluorouracil; LV = leucovorin; WHO = World Health Organization; CTC = Common Toxicity Criteria; OR = odds ratio; ECOG = Eastern Cooperative Oncology Group.

\(^{a}\) Patients were randomized to either 30 or 60 minutes of oral cryotherapy.

\(^{b}\) All 67 patients were randomized sequentially in a crossover design during three cycles of therapy to flavored ice, plain ice, and no ice.

\(^{c}\) Reported by authors only as OR as odds of symptoms increasing vs. not increasing.

\(^{d}\) 40 patients in total; patients were randomized to either cryotherapy (n=45) or standard care (n=54) initially and then crossed-over at next cycle.

\(^{e}\) Arms A/B/C are chlorhexidine/normal saline/cryotherapy, respectively.
# Table 2

**Studies of Oral Cryotherapy in Hematological Malignancies**

<table>
<thead>
<tr>
<th>Reference</th>
<th>Year</th>
<th>Randomized</th>
<th>No. in Intervention/Control Group</th>
<th>Type of Cryotherapy</th>
<th>Duration of Cryotherapy</th>
<th>Chemo Regimen</th>
<th>Mucositis Staging</th>
<th>Intervention Group</th>
<th>Control Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dumontet¹⁵</td>
<td>1994</td>
<td>No</td>
<td>22/−</td>
<td>Ice chips + cold water</td>
<td>5 min pre melphalan and continued for 30 min</td>
<td>Mel or BEAM ± TBI</td>
<td>WHO, Grade 3-4</td>
<td>TBI: 86% No TBI: 33%</td>
<td>-</td>
</tr>
<tr>
<td>Meloni¹⁶</td>
<td>1996</td>
<td>No</td>
<td>18/−</td>
<td>Ice popsicles</td>
<td>5 min pre, during, and 5 after melphalan infusion</td>
<td>Mel or BEAM</td>
<td>WHO, Grade 4</td>
<td>6%</td>
<td>-</td>
</tr>
<tr>
<td>Aisa³³</td>
<td>2005</td>
<td>No</td>
<td>18/7 (historical control)</td>
<td>Ice chips + cold water</td>
<td>15 min pre and during, until 90 min after melphalan infusion</td>
<td>Mel + Flu ± Other³</td>
<td>CTC, Grade 2-3</td>
<td>11%</td>
<td>86%</td>
</tr>
<tr>
<td>Mori³⁶</td>
<td>2006</td>
<td>No</td>
<td>17/18 b</td>
<td>Ice chips + cold water</td>
<td>15 min pre and during, until 60 or 90 min after melphalan infusion</td>
<td>Mel + Flu ± Other³</td>
<td>CTC, Grade 2-3</td>
<td>60 min: 11.8% 120 min: 11.1%</td>
<td>-</td>
</tr>
<tr>
<td>Lilleby³⁵</td>
<td>2006</td>
<td>Yes</td>
<td>21/20</td>
<td>Ice chips</td>
<td>30 min pre and during, until 6 hours after infusion</td>
<td>Mel</td>
<td>CTC, Grade 3-4</td>
<td>14%</td>
<td>74%</td>
</tr>
<tr>
<td>Svanberg³⁷</td>
<td>2007</td>
<td>Yes</td>
<td>39/39</td>
<td>Ice chips or ice water</td>
<td>During infusion of chemotherapy</td>
<td>Variable</td>
<td>Modified Oral Mucositis Assessment score c</td>
<td>Autologous=1.6 Allogeneic=3.7</td>
<td>4.3 11.6</td>
</tr>
<tr>
<td>Gori³⁹</td>
<td>2007</td>
<td>Yes</td>
<td>62/60</td>
<td>Ice chips</td>
<td>At least 60 min once methotrexate infusion started</td>
<td>Methotrexate</td>
<td>CTC, Grade 3-4</td>
<td>47%</td>
<td>53%</td>
</tr>
<tr>
<td>Bhatt¹⁴</td>
<td>2010</td>
<td>No</td>
<td>12/13 (historical cohort)</td>
<td>Ice chips</td>
<td>30 min prior to until infusion complete</td>
<td>Mel</td>
<td>CTC, Grade 3</td>
<td>17%</td>
<td>38%</td>
</tr>
<tr>
<td>Svanberg³⁸</td>
<td>2010</td>
<td>Yes</td>
<td>39/39</td>
<td>Ice chips or cold water</td>
<td>During infusion of chemotherapy</td>
<td>Variable</td>
<td>WHO, Grade 3-4</td>
<td>36%</td>
<td>62%</td>
</tr>
</tbody>
</table>

Mel = melphalan; BEAM = carmustine, etoposide, cytarabine, and melphalan; TBI = total body irradiation; Flu = fludarabine; WHO = World Health Organization; CTC = Common Toxicity Criteria.

³ Other: included total body irradiation vs. craniospinal irradiation vs. high-dose cytarabine.

b Study compared two different total durations of oral cryotherapy, 60 min (n=17) and 120 min (n=18).

c Based on modified Oral Mucositis Assessment Score; Autologous group (n=62) index ranged 0-5; Allogeneic group (n=16) index ranged 0-16.
## Recent Studies of Scalp Hypothermia

<table>
<thead>
<tr>
<th>Reference</th>
<th>Year</th>
<th>Randomized</th>
<th>No. in Intervention/Control Group</th>
<th>Cooling Method</th>
<th>Chemo Regimen</th>
<th>Hair Loss Grading</th>
<th>Intervention Group</th>
<th>Control Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mols⁶⁸</td>
<td>2009</td>
<td>No</td>
<td>98/168</td>
<td>Paxman system</td>
<td>AC, FEC, FAC, DAC</td>
<td>No wig required</td>
<td>52%</td>
<td>3%</td>
</tr>
<tr>
<td>Auvinen⁶⁹</td>
<td>2010</td>
<td>No</td>
<td>64/−</td>
<td>Gel-cap</td>
<td>A, D, D+FEC, FEC</td>
<td>Modified CTC, a</td>
<td>69% 17%</td>
<td>-</td>
</tr>
<tr>
<td>Kargar⁷⁰</td>
<td>2011</td>
<td>No</td>
<td>31/32</td>
<td>Penguin Cap</td>
<td>D, ABVD, BEP, CHOP</td>
<td>WHO, Grade 3 or 4</td>
<td>23% 50%</td>
<td>61% 75%</td>
</tr>
<tr>
<td>van den Hurk⁷¹</td>
<td>2012</td>
<td>No (registry)</td>
<td>1411/−</td>
<td>Various</td>
<td>Various</td>
<td>No wig required</td>
<td>50%</td>
<td>-</td>
</tr>
<tr>
<td>van den Hurk⁷²</td>
<td>2012</td>
<td>No b</td>
<td>53/15</td>
<td>Paxman system</td>
<td>D</td>
<td>No wig required</td>
<td>79% 95%</td>
<td>27%</td>
</tr>
<tr>
<td>Lemieux³¹²</td>
<td>2012</td>
<td>No</td>
<td>110/26</td>
<td>Penguin Cap or Dignicap</td>
<td>Various</td>
<td>Success per, c</td>
<td>34% 49%</td>
<td>9% 4%</td>
</tr>
<tr>
<td>Van den Hurk⁷³</td>
<td>2013</td>
<td>No</td>
<td>160/86</td>
<td>Paxman system</td>
<td>Various</td>
<td>WHO, Grade 2</td>
<td>50% 30%</td>
<td>7% 91%</td>
</tr>
<tr>
<td>Betticher⁷⁴</td>
<td>2013</td>
<td>No</td>
<td>128/71/39 d</td>
<td>Paxman system or cold cap</td>
<td>D as weekly or Q 3 weekly ± other chemotherapy</td>
<td>WHO Grade 3 or 4</td>
<td>23% 7% 27% 8%</td>
<td>74% 17%</td>
</tr>
</tbody>
</table>

AC = adriamycin, cyclophosphamide; FEC = 5-fluorouracil, epirubicin, cyclophosphamide; FAC = 5-fluorouracil, adriamycin, cyclophosphamide; DAC = docetaxel, adriamycin, cyclophosphamide; A = adriamycin; D = docetaxel; ABVD = adriamycin, bleomycin, vinblastine, dacarbazine; BEP = bleomycin, etoposide, cisplatin; CHOP = cyclophosphamide, adriamycin and vincristine plus prednisolone; WHO = World Health Organization; CTC = Common Toxicity Criteria; Q = every/

a Modified CTC were used: Grade 0 = No hair loss, Grade 1 = Thinning of hair, and Grade 2 = Patchy or major hair loss or complete alopecia.

b The study was an observational study followed by randomization if the initial phase of study suggested significant benefit.

c Success was defined as moderate, little, or no hair loss.

d Study compared three groups: Paxman system=128, cold cap=71, and control=39.
## Table 4

Studies of Regional Hypothermia for the Prevention of Onycholysis

<table>
<thead>
<tr>
<th>Reference</th>
<th>Year</th>
<th>No. in Intervention/Control Group</th>
<th>Chemo Regimen</th>
<th>Nail Toxicity Scale</th>
<th>Intervention Group</th>
<th>Control Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scotté a</td>
<td>2005</td>
<td>45</td>
<td>Docetaxel 75 mg/m² ± other chemotherapy</td>
<td>CTC, Grade 1 or 2</td>
<td>27%</td>
<td>51%</td>
</tr>
<tr>
<td>Scotté b</td>
<td>2008</td>
<td>50 (foot)</td>
<td>Docetaxel 70-100 mg/m² ± other chemotherapy</td>
<td>CTC, Grade 1 or 2</td>
<td>0%</td>
<td>21%</td>
</tr>
<tr>
<td>Sakurai c</td>
<td>2009</td>
<td>70/52</td>
<td>Docetaxel 75 mg/m² ± other chemotherapy</td>
<td>CTC, Grade 1 or 2</td>
<td>54%</td>
<td>74%</td>
</tr>
<tr>
<td>Hayashi d</td>
<td>2009</td>
<td>52</td>
<td>Docetaxel 75 mg/m² + Cyclophosphamide</td>
<td>CTC, Grade 1 or 2</td>
<td>19%</td>
<td>37%</td>
</tr>
<tr>
<td>Ishiguro e</td>
<td>2011</td>
<td>23</td>
<td>Docetaxel ≥40 mg/m² ± other chemotherapy</td>
<td>CTC, Grade 1 or 2</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Can f</td>
<td>2012</td>
<td>55/145</td>
<td>Docetaxel or paclitaxel (variable dose) ± other chemotherapy</td>
<td>CTC, Grade 1, 2, or 3</td>
<td>Paclitaxel Q 7 days, Paclitaxel Q 21 days, Docetaxel Q 21 days</td>
<td>56% 50% 38%</td>
</tr>
</tbody>
</table>

CTC = Common Toxicity Criteria.

a All studies, unless indicated otherwise, used one hand as the control and the other as the intervention.

b All studies, unless indicated otherwise, used a frozen glove at −25 to −30°C for a duration of 90 minutes: 15 minutes prior to, during, and 15 minutes after the infusion of docetaxel.

c Both hands in intervention group were provided with frozen group; control group did not receive any intervention.

d Frozen glove was worn for 15 minutes prior to, during, and 30 minutes after the infusion of docetaxel.

e One hand received standard frozen glove and other received frozen glove at −10 to −20°C for 60 min (see text).

f Intervention group received frozen gloves and socks on all extremities; control group received neither.